Logo image of BEAM

BEAM THERAPEUTICS INC (BEAM) Stock Fundamental Analysis

NASDAQ:BEAM - Nasdaq - US07373V1052 - Common Stock - Currency: USD

30.43  -2.71 (-8.18%)

After market: 31 +0.57 (+1.87%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to BEAM. BEAM was compared to 572 industry peers in the Biotechnology industry. While BEAM has a great health rating, there are worries on its profitability. While showing a medium growth rate, BEAM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BEAM had negative earnings in the past year.
BEAM had a negative operating cash flow in the past year.
BEAM had negative earnings in each of the past 5 years.
In the past 5 years BEAM reported 4 times negative operating cash flow.
BEAM Yearly Net Income VS EBIT VS OCF VS FCFBEAM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M

1.2 Ratios

BEAM's Return On Assets of -12.26% is amongst the best of the industry. BEAM outperforms 86.50% of its industry peers.
BEAM has a better Return On Equity (-18.15%) than 87.21% of its industry peers.
Industry RankSector Rank
ROA -12.26%
ROE -18.15%
ROIC N/A
ROA(3y)-18.59%
ROA(5y)-31.49%
ROE(3y)-32.58%
ROE(5y)-53.55%
ROIC(3y)N/A
ROIC(5y)N/A
BEAM Yearly ROA, ROE, ROICBEAM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400

1.3 Margins

BEAM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BEAM Yearly Profit, Operating, Gross MarginsBEAM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -200K -400K -600K -800K

More info and screens

7

2. Health

2.1 Basic Checks

BEAM does not have a ROIC to compare to the WACC, probably because it is not profitable.
BEAM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BEAM has been increased compared to 5 years ago.
Compared to 1 year ago, BEAM has an improved debt to assets ratio.
BEAM Yearly Shares OutstandingBEAM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
BEAM Yearly Total Debt VS Total AssetsBEAM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 500M 1B

2.2 Solvency

An Altman-Z score of 3.15 indicates that BEAM is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.15, BEAM is doing good in the industry, outperforming 74.96% of the companies in the same industry.
There is no outstanding debt for BEAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.15
ROIC/WACCN/A
WACC9.44%
BEAM Yearly LT Debt VS Equity VS FCFBEAM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M

2.3 Liquidity

BEAM has a Current Ratio of 5.69. This indicates that BEAM is financially healthy and has no problem in meeting its short term obligations.
BEAM has a Current ratio of 5.69. This is comparable to the rest of the industry: BEAM outperforms 59.68% of its industry peers.
A Quick Ratio of 5.69 indicates that BEAM has no problem at all paying its short term obligations.
BEAM has a better Quick ratio (5.69) than 60.04% of its industry peers.
Industry RankSector Rank
Current Ratio 5.69
Quick Ratio 5.69
BEAM Yearly Current Assets VS Current LiabilitesBEAM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.79% over the past year.
Looking at the last year, BEAM shows a very strong growth in Revenue. The Revenue has grown by 328.69%.
BEAM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 2563.03% yearly.
EPS 1Y (TTM)57.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.1%
Revenue 1Y (TTM)328.69%
Revenue growth 3Y2563.03%
Revenue growth 5YN/A
Sales Q2Q%-17.01%

3.2 Future

The Earnings Per Share is expected to decrease by -14.79% on average over the next years. This is quite bad
BEAM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.04% yearly.
EPS Next Y-151.11%
EPS Next 2Y-60%
EPS Next 3Y-33.14%
EPS Next 5Y-14.79%
Revenue Next Year-35.08%
Revenue Next 2Y-13.74%
Revenue Next 3Y-6.96%
Revenue Next 5Y23.04%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BEAM Yearly Revenue VS EstimatesBEAM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
BEAM Yearly EPS VS EstimatesBEAM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BEAM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BEAM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BEAM Price Earnings VS Forward Price EarningsBEAM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BEAM Per share dataBEAM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5

4.3 Compensation for Growth

A cheap valuation may be justified as BEAM's earnings are expected to decrease with -33.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-60%
EPS Next 3Y-33.14%

More info and screens

0

5. Dividend

5.1 Amount

BEAM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEAM THERAPEUTICS INC

NASDAQ:BEAM (2/21/2025, 8:03:04 PM)

After market: 31 +0.57 (+1.87%)

30.43

-2.71 (-8.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/bmo
Earnings (Next)03-04 2025-03-04/amc
Inst Owners95.33%
Inst Owner Change2.46%
Ins Owners1.42%
Ins Owner Change2.83%
Market Cap2.52B
Analysts80.87
Price Target48.72 (60.11%)
Short Float %12.29%
Short Ratio8.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.14%
Min EPS beat(2)0.76%
Max EPS beat(2)3.51%
EPS beat(4)4
Avg EPS beat(4)72.07%
Min EPS beat(4)0.76%
Max EPS beat(4)267.72%
EPS beat(8)8
Avg EPS beat(8)48.64%
EPS beat(12)11
Avg EPS beat(12)34.52%
EPS beat(16)12
Avg EPS beat(16)-7.39%
Revenue beat(2)0
Avg Revenue beat(2)-11.07%
Min Revenue beat(2)-18.62%
Max Revenue beat(2)-3.52%
Revenue beat(4)1
Avg Revenue beat(4)370.21%
Min Revenue beat(4)-57.18%
Max Revenue beat(4)1560.15%
Revenue beat(8)4
Avg Revenue beat(8)201.43%
Revenue beat(12)8
Avg Revenue beat(12)327.21%
Revenue beat(16)11
Avg Revenue beat(16)318.16%
PT rev (1m)-3.08%
PT rev (3m)-1.8%
EPS NQ rev (1m)3.94%
EPS NQ rev (3m)3.36%
EPS NY rev (1m)0.89%
EPS NY rev (3m)1%
Revenue NQ rev (1m)19.36%
Revenue NQ rev (3m)16.18%
Revenue NY rev (1m)1.13%
Revenue NY rev (3m)2.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.21
P/FCF N/A
P/OCF N/A
P/B 3.18
P/tB 3.18
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)-4.86
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS4.22
BVpS9.56
TBVpS9.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.26%
ROE -18.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.59%
ROA(5y)-31.49%
ROE(3y)-32.58%
ROE(5y)-53.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.09%
Cap/Sales 2.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.69
Quick Ratio 5.69
Altman-Z 3.15
F-Score6
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)380.94%
Cap/Depr(5y)369.14%
Cap/Sales(3y)59.86%
Cap/Sales(5y)28915.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.1%
EPS Next Y-151.11%
EPS Next 2Y-60%
EPS Next 3Y-33.14%
EPS Next 5Y-14.79%
Revenue 1Y (TTM)328.69%
Revenue growth 3Y2563.03%
Revenue growth 5YN/A
Sales Q2Q%-17.01%
Revenue Next Year-35.08%
Revenue Next 2Y-13.74%
Revenue Next 3Y-6.96%
Revenue Next 5Y23.04%
EBIT growth 1Y54.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.1%
EBIT Next 3Y-6.41%
EBIT Next 5Y6.78%
FCF growth 1Y-468.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-245.21%
OCF growth 3YN/A
OCF growth 5YN/A